Carotid intima-media thickness measurements: Techniques and clinical relevance

Atherosclerosis is a systemic disease that is responsible for most cardiovascular events and stroke. Epidemiologic studies and intervention trials based on the incidence of acute vascular disease end points require years of follow-up, the participation of large populations, or both. As a consequence, such studies consume considerable time and financial resources. The use of surrogate markers, therefore, is of paramount relevance because it allows researchers to have reliable data in less time and from reduced populations. Intima-media thickness (IMT) measured by B-mode ultrasound is the most studied surrogate marker and has been validated by official medical agencies. In this article, we review the most important technical considerations related to its measurement and highlight issues that should be systematically addressed in IMT-related studies. In summary, the use of IMT as an end point in clinical studies is of great value, but several technical limitations might jeopardize its interpretation.

[1]  P Pignoli,et al.  Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. , 1986, Circulation.

[2]  J. Edelstein,et al.  Ultrasonic-pathological comparison of the human arterial wall. Verification of intima-media thickness. , 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

[3]  G. Gamble,et al.  B-mode ultrasound images of the carotid artery wall: correlation of ultrasound with histological measurements. , 1993, Atherosclerosis.

[4]  R A Kronmal,et al.  Thickening of the carotid wall. A marker for atherosclerosis in the elderly? Cardiovascular Health Study Collaborative Research Group. , 1996, Stroke.

[5]  A. Zwinderman,et al.  Variance components analysis of carotid and femoral intima-media thickness measurements. REGRESS Study Group, Interuniversity Cardiology Institute of The Netherlands, Utrecht, The Netherlands. Regression Growth Evaluation Statin Study. , 1998, Ultrasound in medicine & biology.

[6]  A. Zwinderman,et al.  B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). , 1998, Journal of the American College of Cardiology.

[7]  R. Kronmal,et al.  Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. , 1999, The New England journal of medicine.

[8]  Eary,et al.  CAROTID-ARTERY INTIMA AND MEDIA THICKNESS AS A RISK FACTOR FOR MYOCARDIAL INFARCTION AND STROKE IN OLDER ADULTS , 2000 .

[9]  G. Feder,et al.  Estimating cardiovascular risk for primary prevention: outstanding questions for primary care , 2000, BMJ : British Medical Journal.

[10]  Diederick E Grobbee,et al.  Carotid Intima-Media Thickness Measurements in Intervention Studies: Design Options, Progression Rates, and Sample Size Considerations: A Point of View , 2003, Stroke.

[11]  Efficacy and safety of statin therapy in children with familial hypercholesterolemia: A randomized controlled clinical trial☆ , 2004 .

[12]  Carotid intima-media thickness testing: technical considerations. , 2004, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[13]  S. Feinstein,et al.  Effect of contrast enhancement on measurement of carotid artery intimal medial thickness , 2004 .

[14]  Aaron Fenster,et al.  3D Ultrasound Measurement of Change in Carotid Plaque Volume: A Tool for Rapid Evaluation of New Therapies , 2005, Stroke.

[15]  James G Terry,et al.  Carotid intimal-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors , 2005, Current controlled trials in cardiovascular medicine.

[16]  Candesartan- and Atenolol-Based Treatments Induce Different Patterns of Carotid Artery and Left Ventricular Remodeling in Hypertension , 2006 .

[17]  M. Nieminen,et al.  Association of carotid intima-media thickness with angiographic severity and extent of coronary artery disease. , 2006, The American journal of cardiology.

[18]  G. Su,et al.  Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension. , 2006, Clinical chemistry.

[19]  Y. Yamasaki,et al.  Rationale and protocol of a trial for prevention of diabetic atherosclerosis by using antiplatelet drugs: study of Diabetic Atherosclerosis Prevention by Cilostazol (DAPC study) , 2006, Cardiovascular diabetology.

[20]  D. Berman,et al.  From Vulnerable Plaque to Vulnerable Patient—Part III: Executive Summary of the Screening for Heart Attack Prevention and Education (SHAPE) Task Force Report , 2006 .

[21]  T. Buchanan,et al.  Effect of peroxisome proliferator-activated receptor gamma agonist treatment on subclinical atherosclerosis in patients with insulin-requiring type 2 diabetes. , 2006, Diabetes care.

[22]  S. Feinstein,et al.  Contrast ultrasound imaging of the carotid artery vasa vasorum and atherosclerotic plaque neovascularization. , 2006, Journal of the American College of Cardiology.

[23]  Eric Vicaut,et al.  Carotid artery intima media thickness, plaque and framingham cardiovascular score in Asia, Africa/Middle East and Latin America: the PARC-AALA Study , 2007, The International Journal of Cardiovascular Imaging.

[24]  D. Grobbee,et al.  The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness: the Osteoporosis Prevention and Arterial effects of tiboLone (OPAL) study. , 2004, European heart journal.

[25]  S. Haffner,et al.  Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. , 2006, JAMA.

[26]  E. Vicaut,et al.  Mannheim Carotid Intima-Media Thickness Consensus (2004–2006) , 2006, Cerebrovascular Diseases.

[27]  Allen J. Taylor,et al.  The effect of 24 months of combination statin and extended-release niacin on carotid intima‐media thickness: ARBITER 3* , 2006, Current medical research and opinion.

[28]  Diederick E Grobbee,et al.  Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. , 2007, JAMA.

[29]  G. Paolisso,et al.  Raloxifene slows down the progression of intima-media thickness in postmenopausal women , 2007, Menopause.

[30]  Christopher B. Kendall,et al.  Clinical use of carotid intima-media thickness: review of the literature. , 2007, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[31]  Elena Tremoli,et al.  Carotid intima-media thickness by B-mode ultrasound as surrogate of coronary atherosclerosis: correlation with quantitative coronary angiography and coronary intravascular ultrasound findings. , 2007, European heart journal.

[32]  L. Bortolotto,et al.  Effects of continuous positive airway pressure on early signs of atherosclerosis in obstructive sleep apnea. , 2007, American journal of respiratory and critical care medicine.

[33]  R. Vigersky,et al.  A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. , 2007, American heart journal.

[34]  Gerald F Watts,et al.  Carotid intima-medial thickness measured on multiple ultrasound frames: evaluation of a DICOM-based software system , 2007, Cardiovascular ultrasound.

[35]  John Wikstrand,et al.  Methodological considerations of ultrasound measurement of carotid artery intima–media thickness and lumen diameter , 2007, Clinical physiology and functional imaging.

[36]  J. Price,et al.  Ankle brachial index and intima media thickness predict cardiovascular events similarly and increased prediction when combined. , 2007, Journal of clinical epidemiology.

[37]  T. Matsuo,et al.  Uremic hyperhomocysteinemia: A randomized trial of folate treatment for the prevention of cardiovascular events , 2007, Hemodialysis international. International Symposium on Home Hemodialysis.

[38]  Allen J. Taylor,et al.  Design and Rationale of the ARBITER 6 Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol)-6-HDL and LDL Treatment Strategies in Atherosclerosis (HALTS) , 2007, Cardiovascular Drugs and Therapy.

[39]  D. Grobbee,et al.  Effect of Torcetrapib on Carotid Atherosclerosis in Familial Hypercholesterolemia , 2007 .

[40]  A. Gómez de la Cámara,et al.  Effect of folic acid treatment on carotid intima-media thickness of patients with coronary disease. , 2007, International journal of cardiology.

[41]  P. Nilsson,et al.  Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study , 2007, Journal of internal medicine.

[42]  C. Held,et al.  Irbesartan reduces common carotid artery intima‐media thickness in hypertensive patients when compared with atenolol: the Swedish Irbesartan Left Ventricular Hypertrophy Investigation versus Atenolol (SILVHIA) study , 2007, Journal of internal medicine.

[43]  Y. Tamura,et al.  Nateglinide Reduces Carotid Intima-Media Thickening in Type 2 Diabetic Patients Under Good Glycemic Control , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[44]  K. Sutton-Tyrrell,et al.  Fish consumption and early atherosclerosis in middle-aged men. , 2007, Metabolism: clinical and experimental.

[45]  Matthias W. Lorenz,et al.  Prediction of Clinical Cardiovascular Events With Carotid Intima-Media Thickness: A Systematic Review and Meta-Analysis , 2007, Circulation.

[46]  H. Itoh,et al.  Add-on Amlodipine Improves Arterial Function and Structure in Hypertensive Patients Treated With an Angiotensin Receptor Blocker , 2007, Journal of cardiovascular pharmacology.

[47]  Christopher B. Kendall,et al.  Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. , 2008, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[48]  G. Hankey,et al.  Ultrasound settings significantly alter arterial lumen and wall thickness measurements , 2008, Cardiovascular ultrasound.

[49]  A. Michałek [Commentary to the article: Kastelein JJ, Akdim F, Stroes ES, et al.; ENHANCE Investigators. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 2008; 358: 1431-43 ]. , 2008, Kardiologia polska.

[50]  Effect of Lower Targets for Blood Pressure and LDL Cholesterol on Atherosclerosis in Diabetes: The SANDS Randomized Trial , 2008 .

[51]  Vicente Gilsanz,et al.  Reproducibility of carotid intima-media thickness measurements in young adults. , 2008, Radiology.

[52]  Luni Chen,et al.  Simvastatin with or without ezetimibe in familial hypercholesterolemia. , 2008, The New England journal of medicine.

[53]  V. Rousson,et al.  High-dose atorvastatin in peripheral arterial disease (PAD): Effect on endothelial function, intima-media-thickness and local progression of PAD , 2007, Thrombosis and Haemostasis.

[54]  J. Stockman,et al.  Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): a randomised, double-blind trial , 2009 .